Meeting
2013 ASCO Annual Meeting
Phase I study of c-Met inhibitor ARQ197 in combination with FOLFOX for the treatment of patients with advanced solid tumors.
Authors
Suzanne Fields Jones
Sarah Cannon Research Institute, Nashville, TN
Suzanne Fields Jones , Carla Kurkjian , Manish R. Patel , Jeffrey R. Infante , Howard A. Burris III, F Anthony Greco , Michael Brian Hemphill , Adil I. Mohyuddin , Dana Shelton Thompson , Patrick Murphy , Eric Raefsky , Johanna C. Bendell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Cell Cycle and Checkpoints
Clinical Trial Registration Number
NCT01611857
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2544)
DOI
10.1200/jco.2013.31.15_suppl.2544
Abstract #
2544
Poster Bd #
2D
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors.
First Author: Iwona A. Lugowska
Poster
2013 ASCO Annual Meeting
Phase I study of the HSP90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.
First Author: Shubham Pant
Poster
2024 ASCO Annual Meeting
Apatinib and camrelizumab plus Intravenous FOLFOX or hepatic arterial infusion chemotherapy with FOLFOX for advanced HCC: A multicenter, prospective, randomized phase III trial.
First Author: Xu Yunxiuxiu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.
First Author: Kunihiro Fushiki